Every Celva cell is allogeneic.
If you came here to learn what Celva actually uses: we don't use your own cells. Every cell we infuse is donor-derived, screened, and manufactured ahead of time. The lone exception is PRP, drawn from your own blood in select spine cases, and it is not a stem cell product.
The two architectures, at a glance.
Autologous therapy uses the patient's own cells. Harvest, process, return to the same person. The cells are biologically identical to the patient (same DNA, same MHC markers), so rejection is not a concern.
Allogeneic therapy uses cells from another person, a donor. The donor is typically rigorously screened. For mesenchymal stem cells, the donor is most commonly a consented mother contributing umbilical cord tissue after delivery.
In conventional medicine (kidney transplants, bone marrow transplants for leukemia), allogeneic transfers raise the immunology challenges patients have heard about: HLA matching, immunosuppressive medication, graft-versus-host disease. But mesenchymal stem cells are biologically different. They are immunoprivileged: they express low levels of MHC class II molecules and lack co-stimulatory molecules, which is why they don't trigger the conventional rejection cascade. This is why allogeneic MSC therapy can be administered without HLA matching and without immunosuppression. It is a different biology than allogeneic organ transplantation.
Two pathways, two operational realities.
Autologous lives inside a single procedure room and a single day. Allogeneic lives across a donor screening, a cGMP facility, and a clinical-supply chain, with the patient appearing only at the end.
Patient arrives
Procedure begins under local or general anesthesia.
Harvest
Bone marrow aspirate or fat liposuction. ~10M nucleated cells.
Minimal processing
Centrifuge / filter. No real expansion. No batch QC.
Return same-day
Injected or infused back into the same patient.
Consented donor
Screened mother donates cord tissue post-delivery. Pathogen panel.
cGMP expansion
Isolated MSCs expanded over weeks. 100M+ per batch.
Batch testing
Sterility, identity, viability, potency, endotoxin, mycoplasma.
Cryo → bedside
Thawed and prepped day of treatment, viability re-confirmed post-thaw before the dose is drawn.
Six axes, plotted side by side.
Each row places autologous and allogeneic against each other on the dimension that matters clinically. The pip position is qualitative, not metric.
Every Celva cell is allogeneic.
This is the point patients most often get backwards, so it's worth stating plainly: Celva does not use your own cells. Every cell we infuse is allogeneic, donor-derived and manufactured ahead of time. Umbilical-cord MSCs for systemic work, and donor bone-marrow MSCs or chondrocytes at a target site when a case calls for it. None of it is harvested from your body.
The one thing some patients receive that does come from their own body is PRP, platelet-rich plasma, and it is not a stem cell product. PRP is a small concentrate of growth factors spun down from your own blood. It plays a limited, optional role as a local adjunct in select spine cases, never as a substitute for the cell therapy and never the main event. If you have read "autologous" elsewhere and assumed it meant your own stem cells, this is the distinction that matters: our cells are donor cells, start to finish.
The case for allogeneic donor cells.
The biological case for allogeneic cord-derived MSCs comes down to four properties autologous cells cannot match:
1. Cell age
Allogeneic cord cells are newborn cells, they've existed for nine months. Autologous cells are the patient's age. For older patients, this is a meaningful gap. Older cells have shorter telomeres, accumulated mutations, lower proliferative capacity, and weaker secretome (the cocktail of growth factors and signaling molecules MSCs release).
MSCs are immunoprivileged.
Conventional allogeneic transplant (kidney, heart) triggers rejection because donor cells display surface markers that the recipient's immune system reads as foreign. MSCs largely don't show those markers, so the rejection cascade never starts.
Visible to the immune system.
Functionally invisible.
2. Yield
A single cord can yield enough starting tissue to expand into hundreds of millions of cells across multiple batches. A single bone marrow pull yields perhaps 10 million nucleated cells, of which only a fraction are MSCs. Allogeneic manufacturing produces large doses; autologous harvest produces small doses.
3. Standardization
Every patient receiving cells from the same allogeneic batch receives the same product: same characterization, same potency, same release testing. Autologous therapy is by definition variable: each patient is their own batch, with their own variable yield, viability, and potency.
4. No patient-side harvest
The patient does not undergo a procedure to produce cells. No bone marrow aspirate. No liposuction. No anesthesia. No same-day surgical burden on a body that's already managing a chronic condition.
The case for autologous (your own) cells.
Autologous therapy is not biologically inferior in every context. There are real reasons it persists as a category:
1. Zero rejection risk by definition
Autologous cells cannot trigger immune rejection. While allogeneic MSCs are largely immunoprivileged, "largely" is not "always." Rare transient immune responses to allogeneic infusions are documented in the literature. With autologous, this category of risk does not exist.
2. Established U.S. legal pathway
The FDA's "same surgical procedure" exception covers minimally manipulated autologous tissue transferred during a single surgical encounter. This is the legal basis for most U.S. stem-cell-style clinics offering bone marrow or adipose-derived treatments without an IND. Allogeneic therapy in the U.S. requires an Investigational New Drug application, a path that takes years and costs millions.
3. Familiar regulatory profile for clinicians
Autologous cell therapy looks more like conventional clinical practice. The harvest is a procedure clinicians know how to perform. The processing is minimal. The product is the patient's own tissue. For regulators and clinicians, it sits in familiar territory.
4. When the indication calls for it
For some applications, particularly orthopedic point-of-care injections, autologous bone marrow concentrate has a real evidence base. The question is not "is autologous valid": it's "is autologous the right tool for this condition, at this dose, in this patient?"
What the clinical literature looks like.
The published evidence base for mesenchymal stem cell therapy spans hundreds of clinical trials. The largest body of trials uses allogeneic cells, typically umbilical cord-derived, for indications ranging from osteoarthritis to graft-versus-host disease to autoimmune conditions to wound healing.
Allogeneic MSC products have received conditional or full marketing authorization in several jurisdictions outside the U.S. The FDA has approved one allogeneic MSC product. Ryoncil, for steroid-refractory acute graft-versus-host disease in pediatric patients. The autologous evidence base is also substantial, but more concentrated in orthopedics and harvest-based research protocols.
Approvals are geographic.
"Hundreds of trials" is not the same as "proven for your condition." Stem cell therapy is studied across many indications; the strength of evidence varies enormously by indication. If a clinic claims their product is "FDA-cleared" or "proven" for your condition, ask for the specific trial, the patient population, and the endpoint. More on trials vs. treatment.
How to read a clinic's source claims.
When evaluating a clinic, the source language tells you a lot. Some patterns:
Stem cells
Source not named. Either marketing imprecision or actively avoiding the question. A serious program names the tissue, the modality, and the manufacturer.
Your own cells
Usually an autologous-only program operating in the U.S. under the same-surgical-procedure framework. May be the right tool, particularly for orthopedic point-of-care. Not the same therapy as cord-derived allogeneic.
Umbilical cord stem cells
Allogeneic, cord-derived. Often Wharton's jelly MSCs expanded in a cGMP facility. The strongest source for systemic chronic-disease applications. if the manufacturing is real.
SVF or stromal vascular fraction
Adipose-derived autologous, minimally manipulated. Usually same-day harvest-and-inject. The yield and viability vary by harvest, by patient, by clinic.
Exosomes · growth factors · stem cell secretions
Different category. These are cell-derived products, not living cells. Different evidence base, different mechanism, different regulatory framing.
A combination of multiple sources
Sometimes legitimate (for example, allogeneic cord MSCs systemically plus allogeneic bone-marrow MSCs or chondrocytes at the target site). Sometimes vague language hiding a thin product. Press for specifics.